Z94.81 Insurance Policy Changes

ICD-10 Z94.81 is officially defined as "Bone marrow transplant status." code Z94.81 is referenced in 8 tracked payer policy changes from Blue Cross & Blue Shield of Mississippi and Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code Z94.81 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Blue Cross & Blue Shield of Mississippi · Effective Jun 15, 2026Medium impact
Immunoglobulin Therapy
BCBSMS's Immunoglobulin Therapy policy states that prior authorization is required, and the 06/15/2026 update added Yimmugo to the products not covered on any BCBSMS Formulary. The same effective-dated update revised the medically necessary criteria for formulary intravenous and subcutaneous immunoglobulin therapy and changed the investigational list to specify sepsis in adults. Alyglo, Asceniv, Bivigam, Cuvitru, Flebogamma DIF, Gammagard S/D, Gammaplex, GamaSTAN, Hyqvia, Panzyga and Yimmugo are listed as not covered.
Aetna · Identified Oct 1, 2026Medium impact
Donor Lymphocyte Infusion (CPB 0638, reviewed 2026-09-29)
Aetna considers donor lymphocyte infusion medically necessary for persons who have had a prior medically necessary allogeneic bone marrow or peripheral stem cell transplantation. Several uses are considered experimental, investigational, or unproven, including GCSF-stimulated donor lymphocyte infusions for relapsed disease, intrathecal donor lymphocyte infusion, modified donor lymphocytes, reduced-dose infusion for Epstein-Barr virus-related post-transplant lymphoproliferative disease, pre-transplant infusion of extracorporeal photochemotherapy-treated donor lymphocytes for solid organ transplant, and donor lymphocyte-derived natural killer cells for melanoma. The policy does not apply to FDA-approved chimeric antigen receptor therapy, which is addressed in CPB 0920 and CPB 0924.
Aetna · Identified Sep 30, 2026Medium impact
Palivizumab (Synagis) (CPB 0318, reviewed 2026-08-21)
Aetna's Clinical Policy Bulletin 0318 covers palivizumab (Synagis) for commercial medical plans and requires precertification from participating providers and members in applicable plan designs. Aetna considers palivizumab medically necessary for up to 5 doses per RSV season to prevent serious lower respiratory tract disease caused by RSV when a member has prematurity, chronic lung disease of prematurity, hemodynamically significant congenital heart disease, a congenital airway abnormality, a neuromuscular condition that compromises handling of respiratory secretions, profound immunocompromise, or cystic fibrosis, and the age, gestational age and clinical criteria for that diagnosis are met. Palivizumab is excluded for members who received nirsevimab-alip (Beyfortus) in the same RSV season. Aetna considers the Synagis season to be November 1 through March 31. For off-season requests, 1 dose per request may be authorized, up to 5 doses per RSV season, if RSV activity for the requested region is at least 3% by real-time PCR within 2 weeks of the intended dose. Aetna considers palivizumab experimental and investigational for asthma, Down syndrome, childhood interstitial lung disease, prevention of health-care associated RSV disease, prophylaxis against RSV in immunocompromised adults, and treatment of RSV.
Aetna · Identified Aug 15, 2026Medium impact
Hematopoietic Colony-Stimulating Factors (CSFs) (CPB 0055, reviewed 2026-07-16)
Aetna's Clinical Policy Bulletin 0055 addresses hematopoietic colony-stimulating factors (CSFs) for commercial medical plans, and Medicare criteria are in the Medicare Part B Criteria. Precertification is required for long-acting G-CSF products (including Neulasta and Rolvedon), short-acting G-CSF products (including Neupogen and Granix) and Leukine (sargramostim) in applicable plan designs. Aetna considers short-acting G-CSF products medically necessary for prevention or treatment of febrile neutropenia, and long-acting products for prevention of febrile neutropenia, in cancer members receiving myelosuppressive chemotherapy when the listed criteria are met, and considers all other indications, including use as adjunctive therapy to antibiotics in uncomplicated febrile neutropenia, experimental, investigational, or unproven.
Aetna · Identified Aug 15, 2026Medium impact
Extracorporeal Photochemotherapy (Photopheresis) (CPB 0241, reviewed 2026-04-13)
Aetna considers extracorporeal photochemotherapy (photopheresis, ECP) medically necessary for erythrodermic variants of cutaneous T cell lymphoma, acute cardiac allograft rejection refractory to standard immunosuppressive drug treatment, bronchiolitis obliterans rejection in lung transplants that is refractory to immunosuppressive drug treatment, rejection of other solid organ transplants as a last resort, and graft-versus-host disease after an allogeneic bone marrow or stem cell transplant that is refractory to standard immunosuppressive drug treatment. Aetna considers photopheresis experimental, investigational, or unproven for many other conditions, including atopic dermatitis, multiple sclerosis, Crohn's disease, systemic sclerosis, and type 1 diabetes. Prophylaxis of graft-versus-host disease following allogeneic hematopoietic cell transplantation is also listed as experimental, investigational, or unproven.
Aetna · Identified Aug 14, 2026Medium impact
Donor Lymphocyte Infusion (CPB 0638, reviewed 2025-11-12)
Aetna considers donor lymphocyte infusion (DLI) medically necessary for persons who have had a prior, medically necessary allogeneic bone marrow or peripheral stem cell transplantation. Aetna considers these uses experimental, investigational, or unproven: GCSF-stimulated DLI for relapsed disease after allogeneic hematopoietic cell transplantation, intrathecal DLI, modified donor lymphocytes (such as depleted, expanded, T-cell depleted, CAR-modified or genetically modified cells), pre-transplant infusion of extracorporeal photochemotherapy-treated donor lymphocytes to prevent graft rejection after solid organ transplantation, reduced-dose DLI for Epstein-Barr virus-related post-transplant lymphoproliferative disease, and donor lymphocyte-derived natural killer cells for melanoma. The policy does not apply to FDA-approved CAR T therapy, which involves modification of autologous lymphocytes.
Aetna · Identified Aug 13, 2026Medium impact
Palivizumab (Synagis) (CPB 0318, reviewed 2025-11-24)
Aetna considers palivizumab (Synagis) medically necessary for commercial medical plans for up to 5 doses per RSV season to prevent serious lower respiratory tract disease caused by RSV, when a member has a qualifying diagnosis such as prematurity, chronic lung disease of prematurity, hemodynamically significant congenital heart disease, cystic fibrosis or profound immunocompromise and the associated criteria are met. Palivizumab is excluded for members who have received nirsevimab-alip (Beyfortus) in the same RSV season. The American Academy of Pediatrics stated that in July 2025 it no longer routinely recommends using Synagis.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Plasma Exchange
Plasma exchange is covered as medically necessary for listed conditions, including severe mixed cryoglobulinemia with multiple manifestations, catastrophic antiphospholipid syndrome, thrombotic thrombocytopenic purpura, atypical hemolytic uremic syndrome, HELLP syndrome of pregnancy, chronic inflammatory demyelinating polyradiculoneuropathy, myasthenia gravis in crisis, and ABO-incompatible kidney transplantation. Listed investigational applications include rheumatoid arthritis, systemic lupus erythematosus, sepsis, asthma, neuromyelitis optica, and multiple sclerosis with a chronic progressive or relapsing remitting course. BCBSMS makes no payment for services that are not documented to be medically necessary.

Watch Z94.81

Get one email when a payer policy names Z94.81, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code Z94.81?

There are 8 tracked policy changes affecting code Z94.81, including updates from Blue Cross & Blue Shield of Mississippi, Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code Z94.81?

Payers that have issued tracked updates for code Z94.81 include: Blue Cross & Blue Shield of Mississippi, Aetna.

How do I get notified when code Z94.81 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code Z94.81. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code Z94.81?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Immunoglobulin Therapy

Donor Lymphocyte Infusion (CPB 0638, reviewed 2026-09-29)

Palivizumab (Synagis) (CPB 0318, reviewed 2026-08-21)

Hematopoietic Colony-Stimulating Factors (CSFs) (CPB 0055, reviewed 2026-07-16)

Extracorporeal Photochemotherapy (Photopheresis) (CPB 0241, reviewed 2026-04-13)

Donor Lymphocyte Infusion (CPB 0638, reviewed 2025-11-12)

Palivizumab (Synagis) (CPB 0318, reviewed 2025-11-24)

Plasma Exchange

What insurance policy changes affect code Z94.81?

Which payers have updated policy for code Z94.81?

How do I get notified when code Z94.81 policy changes?

Why do payers change policies for code Z94.81?